Stockscreener 앱 받기
0.0002
100.00%
0.0001
전일 마감가:
$0.0001
열려 있는:
$0.0002
하루 거래량:
620
Relative Volume:
1.57
시가총액:
$N/A
수익:
-
순이익/손실:
$-12.07M
주가수익비율:
-0.000019
EPS:
-10.6183
순현금흐름:
$-16.71M
1주 성능:
+100.00%
1개월 성능:
+100.00%
6개월 성능:
-98.20%
1년 성능:
-99.92%
1일 변동 폭
$0.0002
$0.0002
1주일 범위
$0.0002
$0.0002
52주 변동 폭
$0.0001
$0.021
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Compare VRPX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.0002 | 0 | 0 | -12.07M | -16.71M | -10.62 |
VRTX
Vertex Pharmaceuticals Inc
|
528.19 | 130.67B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
810.24 | 82.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.99 | 61.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
216.00 | 45.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
369.15 | 41.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Virpax Pharmaceuticals, Inc. Revenue Breakdown – OTC:VRPX - TradingView
Form S-1/A Virpax Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to EBITDA forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to book forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to sales forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to revenue forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax Pharmaceuticals, Inc. Actuals & Estimates (OTC:VRPX) - TradingView
Form S-1/A Virpax Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Nigeria
Top Players and Market Competition in the Non-Opioid Pain Patch Industry - openPR.com
VRPX Stock Plummets 95.5% in Pre-Market Trading on NASDAQ - Meyka
Virpax Pharmaceuticals, Inc. (VRPX) - Minichart
Virpax Pharmaceuticals (VRPX) Expected to Announce Earnings on Tuesday - Defense World
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Curanex Pharmaceuticals Shares Fall in Nasdaq Debut - marketscreener.com
Vinay Shah Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
ENSCW Stock Price, News & Analysis - Stock Titan
BTAX Stock Price, News & Analysis - Stock Titan
QBIO Stock Price, News & Analysis - Stock Titan
EVLO Stock Price, News & Analysis - Stock Titan
PXMD Stock Price, News & Analysis - Stock Titan
XSNX Stock Price, News & Analysis - Stock Titan
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - FinancialContent
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - Stock Titan
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
User - The Chronicle-Journal
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Virpax Pharmaceuticals Inc. (VRPX) Quarterly 10-Q Report - qz.com
ADM’s multiple accounting errors and SEC probe are ‘highly concerning’ to investors - Fortune
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - citybiz
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Virpax Pharmaceuticals Inc (VRPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.33%
0.40%
자본화:
|
볼륨(24시간):